Partnering Better Than Solo Play For Biosimilars, Says Dr. Reddy's CEO; Limited Growth In Generics Will Lead To Moves For Innovative Drugs

MUMBAI - With six biosimilar compounds in the works and two launched in the Indian market, India's second largest generic drug maker - Dr. Reddy's Labs - is negotiating with several multinational companies to broaden its presence in Western markets